31,782 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Acquired by Diametric Capital LP

Diametric Capital LP purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 31,782 shares of the company's stock, valued at approximately $252,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Amneal Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 14,841,969 shares of the company's stock worth $117,548,000 after acquiring an additional 218,025 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Amneal Pharmaceuticals by 11.1% in the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock valued at $31,511,000 after purchasing an additional 378,136 shares during the period. State Street Corp raised its position in shares of Amneal Pharmaceuticals by 3.8% in the third quarter. State Street Corp now owns 3,514,721 shares of the company's stock valued at $29,242,000 after purchasing an additional 127,753 shares during the period. Hennessy Advisors Inc. raised its holdings in Amneal Pharmaceuticals by 6.8% in the 4th quarter. Hennessy Advisors Inc. now owns 1,670,600 shares of the company's stock valued at $13,231,000 after acquiring an additional 106,600 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Amneal Pharmaceuticals by 9.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,539,934 shares of the company's stock worth $12,196,000 after acquiring an additional 135,051 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on AMRX shares. StockNews.com lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $10.80.

Amneal Pharmaceuticals Stock Down 5.5 %

Shares of NASDAQ:AMRX traded down $0.43 during midday trading on Friday, hitting $7.38. The stock had a trading volume of 2,530,148 shares, compared to its average volume of 1,383,950. The company has a market capitalization of $2.29 billion, a P/E ratio of -10.85 and a beta of 1.06. The company's 50-day moving average price is $8.36 and its 200-day moving average price is $8.35. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.18 and a fifty-two week high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. During the same quarter in the previous year, the company earned $0.14 earnings per share. Research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. This trade represents a 9.33 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gautam Patel sold 80,000 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the sale, the director now owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. This trade represents a 4.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,222,590 shares of company stock valued at $43,614,546 over the last ninety days. 17.46% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.